Updated time: 2023-08-08 13:55:42
14A-1070605
TW I805777
Castration resistance and metastasis are both characteristics of prostate cancer (PCa) progression. Our study indicated that higher levels of galectin-4, surface sialyated and unsialylated core 1 O-glycans, and the sugar nucleotide donors for the involved glycosyltransferases are expressed in castration-resistant and metastatic PCa in correlation with poor overall survival in patients. Therefore, our method identified a subtype of risky PCa comprising approximately 16% of all patients. PCa patients of this subtype should be actively treated with targeted therapies tailored to the cognate tumors. Conversely, patients with PCa negative for these biomarkers predicted as indolent tumor do not need active treatment.
- Non-invasive assays for PCa patient: by the significantly higher than background levels of sugar nucleotide substrates of O-linked protein glycosylation, proteins conjugated with sialylated and unsialylated core 1 O-glycans, and galectin-4 protein in serum and urine of patients belonging to aggressive PCa.
- Treatment guide: PCa patients with high PSA and high levels of UDP-GlcNAc, UDP-GalNAc, UDP-Gal, CMP-sialic acid, proteins conjugated with sialylated and unsialylated core 1 O-glycans, and galectin-4 are predicted to progress fast on androgen-deprivation therapy and develop metastases. Patients diagnosed with these features are suggested to be treated with inhibitors that downregulate MYC or SOX9 expression in the PCa.
Biochemical assays for the levels of galectin-4 protein, proteins conjugated with sialylated and unsialylated core 1 O-glycans, and nucleotide sugars, such as UDP-GlcNAc, UDP-GalNAc, UDP-Gal and CMP-sialic acid in urine and serum. One can use ion-pair reverse-phase HPLC, LC-MS/MS, and antibodies or sialylated core 1 O-glycan that specifically recognize galectin-4 to detect the subjects of these nominated biomarkers.
Pei-Wen Hsiao, Chin-Hsien Tsai, Sheue-Fen Tzeng, ...
If you are interested in this technology, please fill in the information on the webpage under the manufacturer option (Request for Technology Licensing, Material Transfer, or Sponsored Research) on the website of this office

Screening method for aggressive prostate cancer and the relevant therapeutics for the same subtype